ArticleFrontiers in medicine2025

Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.

Hiroo Fukada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.